This Article Full Text Full Text (PDF) An erratum has been published Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Alert me to new issues of the journal Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Gralla, R. J. Articles by Raftopoulos, H. Search for Related Content PubMed Articles by Gralla, R. J. Articles by Raftopoulos, H. Social Bookmarking                            What's this?

Progress in the Control of Chemotherapy-Induced Emesis: New Agents and New Studies

Because this article has no abstract, we have provided an extract of the first 100 words of the full text.

The marked improvements in the prevention of emesis have become a standard of practice over the last few decades. Carefully designed and conducted studies established type 3 serotonin antagonists with corticosteroids as highly effective in most settings in which emesis was likely. Practice patterns have gradually conformed in most instances to reflect the results of these studies to the point that antiemetics are among the most commonly used drugs in medical oncology.

	Background

 
Risk factors for emesis have been identified and utilized by guideline groups. The most important risk factor is the type of chemotherapy (such as highly or moderately emetic), . . . [Click for More]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?